Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with α2 macroglobulin in serum of rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 67, Issue 1, 2008, Pages 128-130

  Tchetverikov, I ^a   Kraan, M C ^b   Van El, B ^c   Hanemaaijer, R ^c   Degroot, J ^c   Huizinga, T W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; TERIFLUNOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANALYSIS; ARTICLE; BLOOD SAMPLING; CLINICAL STUDY; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SERUM; SYSTEMIC CIRCULATION;

AGED; ALPHA-MACROGLOBULINS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; ISOXAZOLES; MALE; MATRIX METALLOPROTEINASES; METHOTREXATE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PHENYLALANINE; STATISTICS, NONPARAMETRIC; THIOPHENES;

EID: 37749035385     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067827     Document Type: Article

References (15)

1. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4(Suppl 3):S39-49.
2. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
3. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
4. Chong AS, Finnegan A, Jiang X, Gebel H, Sankary HN, Foster P, et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993;55:1361- 6.
5. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression J Immunol 1999;162:2095-102.
6. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
7. Emery P, Bteedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
8. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-9.
9. Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology 2000;39(Suppl 1):48-56.
10. Burger D, Begue-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology 2003;42:89-96.
11. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M. Active leflunomide metabolite inhibits interleukin 1 beta, tumour necrosis factor alpha, nitric oxide, and metalloptoteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003;62:440-3.
12. Firestein GS, Paine MM. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 1992;140:1309-14.
13. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
14. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H. Detetmination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996;23:1599-604.
15. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.